candesartan has been researched along with angiotensin iii in 13 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (38.46) | 18.2507 |
| 2000's | 6 (46.15) | 29.6817 |
| 2010's | 2 (15.38) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Inada, Y; Nishikawa, K; Noda, M; Ojima, M; Sanada, T; Shibouta, Y; Wada, T | 1 |
| Inada, Y; Kohara, Y; Kubo, K; Naka, T; Nishikawa, K; Noda, M; Ojima, M; Sanada, T; Shibouta, Y; Wada, T | 1 |
| Champion, HC; Kadowitz, PJ | 1 |
| Champion, HC; Czapla, MA; Kadowitz, PJ | 1 |
| Inada, Y; Nishikawa, K; Ojima, M; Sanada, T; Shibouta, Y; Wada, T | 1 |
| Hauner, H; Lee, YM; Skurk, T | 1 |
| Carey, RM; Howell, NL; Padia, SH; Siragy, HM | 1 |
| Bie, P; Gammelgaard, I; Wamberg, S | 1 |
| Carey, RM; Fournie-Zaluski, MC; Howell, NL; Kemp, BA; Padia, SH; Roques, BP; Siragy, HM | 1 |
| Carey, RM; Fournie-Zaluski, MC; Howell, NL; Kemp, BA; Padia, SH; Roques, BP | 1 |
| Carey, RM; Gildea, JJ; Howell, NL; Keller, SR; Kemp, BA; Padia, SH | 1 |
| Bell, JF; Carey, RM; Howell, NL; Kemp, BA; Navar, LG; Padia, SH; Rottkamp, DM; Shao, W | 1 |
| Aguilar, MI; Bosnyak, S; Del Borgo, M; Denton, K; Hilliard, L; Jones, ES; Khan, M; Perlmutter, P; Spizzo, I; Walters, P; Wang, Y; Widdop, RE | 1 |
13 other study(ies) available for candesartan and angiotensin iii
| Article | Year |
|---|---|
Effect of an angiotensin II receptor antagonist, CV-11974, and its prodrug, TCV-116, on production of aldosterone.
Topics: Administration, Oral; Adrenocorticotropic Hormone; Aldosterone; Angiotensin II; Angiotensin III; Angiotensin Receptor Antagonists; Animals; Benzimidazoles; Biphenyl Compounds; Cells, Cultured; Corticosterone; Hypertension; Imidazoles; Infusions, Intravenous; Male; Pyridines; Rabbits; Rats; Rats, Inbred SHR; Rats, Wistar; Tetrazoles; Zona Glomerulosa | 1994 |
Pharmacological profile of a highly potent and long-acting angiotensin II receptor antagonist, 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4- yl]methyl]-1H-benzimidazole-7-carboxylic acid (CV-11974), and its prodrug, (+/-)-1-(cyclohexyloxycarbonyloxy)-ethy
Topics: Adrenal Cortex; Angiotensin II; Angiotensin III; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Aorta; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Cattle; Imidazoles; In Vitro Techniques; Iodine Radioisotopes; Kinetics; Losartan; Male; Muscle Contraction; Muscle, Smooth, Vascular; Prodrugs; Protein Binding; Rabbits; Rats; Rats, Sprague-Dawley; Substrate Specificity; Tetrazoles | 1993 |
Analysis of the effects of candesartan in the mesenteric vascular bed of the cat.
Topics: Angiotensin II; Angiotensin III; Angiotensin Receptor Antagonists; Animals; Benzimidazoles; Biphenyl Compounds; Blood Vessels; Cats; Female; Imidazoles; Male; Perfusion; Pressure; Pyridines; Splanchnic Circulation; Tetrazoles | 1997 |
Responses to angiotensin peptides are mediated by AT1 receptors in the rat.
Topics: Angiotensin II; Angiotensin III; Angiotensin Receptor Antagonists; Animals; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Female; Hindlimb; Imidazoles; Losartan; Male; Norepinephrine; Peptide Fragments; Pyridines; Rats; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Receptors, Angiotensin; Tetrazoles | 1998 |
Comparison of the antihypertensive effects of the new angiotensin II (AT1) receptor antagonist candesartan cilexetil (TCV-116) and the angiotensin converting enzyme inhibitor enalapril in rats.
Topics: Administration, Oral; Angiotensin I; Angiotensin II; Angiotensin III; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Bradykinin; Enalapril; Enzyme Activation; Hypertension, Renal; Male; Peptidyl-Dipeptidase A; Rats; Rats, Inbred SHR; Rats, Sprague-Dawley; Rats, Wistar; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Renal Artery; Surgical Instruments; Tetrazoles; Vasoconstrictor Agents | 1996 |
Angiotensin II and its metabolites stimulate PAI-1 protein release from human adipocytes in primary culture.
Topics: Adipose Tissue; Adolescent; Adult; Angiotensin II; Angiotensin III; Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Cells, Cultured; Female; Humans; Middle Aged; Plasminogen Activator Inhibitor 1; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Receptors, Angiotensin; Tetrazoles; Valine; Valsartan | 2001 |
Renal angiotensin type 2 receptors mediate natriuresis via angiotensin III in the angiotensin II type 1 receptor-blocked rat.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin II Type 2 Receptor Blockers; Angiotensin III; Animals; Benzimidazoles; Biphenyl Compounds; Dose-Response Relationship, Drug; Drug Combinations; Imidazoles; Kidney; Natriuresis; Nephrectomy; Pyridines; Rats; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 2; Sodium Chloride, Dietary; Tetrazoles | 2006 |
Systemic effects of angiotensin III in conscious dogs during acute double blockade of the renin-angiotensin-aldosterone-system.
Topics: Aldosterone; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin III; Angiotensin-Converting Enzyme Inhibitors; Animals; Atrial Natriuretic Factor; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Dogs; Dose-Response Relationship, Drug; Enalaprilat; Female; Glomerular Filtration Rate; Metabolic Clearance Rate; Receptor, Angiotensin, Type 1; Renin; Renin-Angiotensin System; Tetrazoles | 2006 |
Intrarenal aminopeptidase N inhibition augments natriuretic responses to angiotensin III in angiotensin type 1 receptor-blocked rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin III; Animals; Benzimidazoles; Biphenyl Compounds; CD13 Antigens; Enzyme Inhibitors; Methionine; Models, Animal; Natriuresis; Natriuretic Agents; Rats; Rats, Sprague-Dawley; Receptors, Angiotensin; Sodium; Tetrazoles | 2007 |
Conversion of renal angiotensin II to angiotensin III is critical for AT2 receptor-mediated natriuresis in rats.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin II Type 2 Receptor Blockers; Angiotensin III; Animals; Benzimidazoles; Biphenyl Compounds; Blood Pressure; CD13 Antigens; Drug Synergism; Female; Glutamyl Aminopeptidase; Imidazoles; Kidney; Methionine; Natriuresis; Pyridines; Rats; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 2; Sodium, Dietary; Sulfonic Acids; Tetrazoles | 2008 |
Intrarenal angiotensin III infusion induces natriuresis and angiotensin type 2 receptor translocation in Wistar-Kyoto but not in spontaneously hypertensive rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin II Type 2 Receptor Blockers; Angiotensin III; Animals; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Cell Membrane; Disease Models, Animal; Female; Hypertension; Imidazoles; Kidney Tubules, Proximal; Natriuresis; Pyridines; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Sodium; Tetrazoles | 2009 |
Intrarenal angiotensin III is the predominant agonist for proximal tubule angiotensin type 2 receptors.
Topics: Angiotensin I; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin II Type 2 Receptor Blockers; Angiotensin III; Animals; Benzimidazoles; Biphenyl Compounds; Female; Imidazoles; Kidney Tubules, Proximal; Models, Animal; Natriuresis; Peptide Fragments; Pyridines; Rats; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 2; Tetrazoles | 2012 |
β-Pro7Ang III is a novel highly selective angiotensin II type 2 receptor (AT2R) agonist, which acts as a vasodepressor agent via the AT2R in conscious spontaneously hypertensive rats.
Topics: Amino Acid Sequence; Analysis of Variance; Angiotensin II Type 2 Receptor Blockers; Angiotensin III; Animals; Aorta, Thoracic; Benzimidazoles; Binding, Competitive; Biphenyl Compounds; Drug Stability; HEK293 Cells; Humans; Hypertension; Imidazoles; In Vitro Techniques; Inhibitory Concentration 50; Isometric Contraction; Male; Mice; Muscle, Smooth, Vascular; Pyridines; Rats; Receptors, Angiotensin; Tetrazoles; Vasoconstrictor Agents; Vasodilation | 2015 |